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Abstract
Background: The rates of resistant microorganisms which complicate the management of healthcare associated
infections (HAIs) are increasing worldwide and getting more serious in developing countries. The objective of this
study was to describe microbiological features and resistance profiles of bacterial pathogens of HAIs in Jimma
University Medical Center (JUMC) in Ethiopia.
Methods: Institution based cross sectional study was carried out on hospitalized patients from May to September,
2016 in JUMC. Different clinical specimens were collected from patients who were suspected to hospital acquired
infections. The specimens were processed to identify bacterial etiologies following standard microbiological methods.
Antibacterial susceptibility was determined in vitro by Kirby-Bauer disk diffusion method following Clinical and
Laboratory Standards Institute guidelines.
Results: Overall, 126 bacterial etiologies were isolated from 118 patients who had HAIs. Of these, 100 (79.4%)
were gram negative and the remaining were gram positive. The most common isolates were Escherichia coli
31(24.6%), Klebsiella species 30(23.8%) and Staphylococcus aureus 26 (20.6%). Of 126 bacterial isolates, 38 (30.
2%), 52 (41.3%), and 24 (19%) were multidrug-resistant (MDR, resistant to at least one agent in three or more
antimicrobial categories), extensively drug resistant (XDR, resistant to at least one agent in all but two or fewer
antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories), pan-drug
resistant (PDR, resistant to all antibiotic classes) respectively. More than half of isolated gram-negative rods
(51%) were positive for extended spectrum beta-lactamase (ESBL) and/or AmpC; and 25% of gram negative
isolates were also resistant to carbapenem antibiotics.
Conclusions: The pattern of drug resistant bacteria in patients with healthcare associated infection at JUMC
is alarming. This calls for coordinated efforts from all stakeholders to prevent HAIs and drug resistance in
the study setting.
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Introduction
The emergence and rapid spread of multidrug resistant
pathogenic bacteria is becoming a global health chal-
lenge [1]. Recent studies showed an increasing rate of
bacterial resistance against available antibiotics. The
problem is more pronounced in developing countries at-
tributed to limited antibiotic option, irrational drug use,
poor drug quality, poor sanitation, malnutrition, poor
and inadequate health care systems, and lack of control
for antibiotic use and stewardship program [2, 3].
In the past few decades, antimicrobial drugs have
saved many lives and reduced the grief of many million
people globally [3]. However, the extraordinary benefits
of antimicrobials in reducing morbidity and mortality
have been challenged by the emergence of drug resistant
bacteria. The recent emergence and spread of these re-
sistant bacteria have become a serious public health con-
cern [4]. Especially, the spread of such bacteria in
resource limited countries would have devastating con-
sequences considering the health infrastructure, anti-
biotic options available and over all resource constraints
observed in such countries [5].
In recent years, high dissemination of ESBL produ-
cing, carbapenem, and methicillin resistant bacteria are
observed worldwide [6, 7]. It is described that the prob-
lem of ESBL-producing organisms is more intense in
developing countries [8]. However, the magnitude of
the problem is still probably underestimated due to in-
adequate or ineffective detection in some clinical set-
tings [3, 7, 9]. ESBLs are a group of plasmid-mediated,
diverse, complex and rapidly evolving enzymes which
are capable of hydrolyzing penicillin’s, broad-spectrum
cephalosporin’s and monobactam’s [10]. Accordingly,
ESBL enzyme producing bacteria have a capacity to re-
sist the action of penicillin’s, broad-spectrum cephalo-
sporin’s and monobactam’s [11]. Furthermore, there is
an evidence indicating that most of ESBL producing
bacteria are also resistant for carbapenem antibiotics
[12, 13]. ESBLs production is most commonly seen
among Gram negative bacteria including Escherichia
coli, Klebsiella pneumoniae, Proteus mirabilis and
Pseudomonas aeruginosa [14].
Infections resulting from antibiotic resistant bac-
teria are more difficult and, in some instances, im-
possible to treat with current available antibiotics.
Such infections lead to higher morbidity and mortal-
ity, imposing huge healthcare cost [15, 16]. In recent
years, varieties of bacteria are becoming resistant
against two or more classes of antibiotics as a result
of selective pressure or horizontal gene transfer. For
instance, the magnitude of resistance seen among E.
coli, S. aureus, Klebsiella species, P. aeruginosa, A.
baumannii, and Enterobacter species is more threat-
ening as these bacteria are the commonest etiologies
for commonly observed hospital and community ac-
quired infections [17, 18].
In Ethiopia, the patterns of antibiotic resistance among
commonly seen bacterial etiologies have been described
previously in different settings [19–21]. However, most
of these studies did not address the magnitude of ESBL
producing and carbapenem resistance patterns compre-
hensively. It is also known that bacterial antibiotic resist-
ance is a dynamic process. Resistance patterns seen in
the past might not be representing the current situation
due to the strong correlation between efficiency of anti-
biotic use and antibiotic resistance. As a result, informa-
tion about the current antibiotic resistance pattern of
bacteria is very vital to understand the dynamic and
trend of resistance.
Clinical characteristics of patients with HAIs at Jimma
University Medical Center have recently been published.
The incidence and overall prevalence of HAIs at the
hospital were 28.15 per 1000 patient days and 19.41% re-
spectively [22]. In the current study, we aimed to deter-
mine the MDR, XDR, PDR, ESBL mediated and
carbapenem resistance patterns of bacteria isolated from
patients with HAIs at the hospital.
Methods and materials
Institution based cross-sectional study was carried out in
all wards of JUMC from May, 2016 to September, 2016.
Totally, 1015 patients were admitted, of these 197 pa-
tients had sign of healthcare associated infection during
the study time and all were taken as study participants.
Microbiological investigation was done for 192 partici-
pants suspected to have healthcare associated infection;
no microbiological test was done for the other five cases
due to inability to obtain proper specimen. Different
clinical specimens (blood, urine, wound swab, pus, and
sputum) were collected aseptically from the patients
with signs of healthcare associated infection. Bacterial
identification was performed by standard microbiological
methods which are adopted from CLSI guideline.
Phenotypic determination of antibiotic susceptibility
patterns
Antibacterial susceptibility of Penicillin (10 μg), Oxacillin
(1 μg), Gentamycin (10 μg), Chloramphenicol (30 μg),
Tetracycline (30 μg) Erythromycin (15 μg), Trimethoprim-
sulfamethoxazole (1.25 g), Clindamycin (2 μg), Cefoxitin
(30 μg), Ciprofloxacin (5 μg), Nitrofurantoin (300 μg), Nor-
floxacin (10 μg), Ampicillin (10 μg), Amoxicillin-clavulanic
acid (10 μg), Ceftriaxone (30 μg), Ceftazidime (30 μg),
Cefepime (30 μg), and Meropenem (10 μg), (Oxoid, UK)
were determined in vitro by Kirby-Bauer disk diffusion
method following Clinical and Laboratory Standards Insti-
tute guidelines [23].
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ESBL and/or AmpC detection
The presence of an ESBL and/or AmpC was determined
with Cefpodoxime (10 μg), Cefotaxime (30 μg), Cefepime
(30 μg) and Ceftazidime (30 μg) containing antibiotic discs
(Mast Group, UK) by disc diffusion confirmation test.
After the discs were inserted on inoculated plates, then
they were incubated at 35–37 °C for 18–24 h aerobically.
Finally, zones of inhibition were read and recorded on
excel sheet. The data from the excel sheet was transported
to Mast group ESBL/AmpC and CARBA plus calculator
spreadsheet (Mast group, UK) and reported as negative or
positive for ESBL or/and AmpC and finally the results
were recorded.
The results were registered as resistant, intermediate
and susceptible; but for the sake of analysis intermediate
and resistant isolates were grouped together as resistant.
Classification of MDR, XDR and PDR were carried out
according to Magiorakos et al, definitions [4]. All the
antibiotic disks were from Oxoid (Oxoid, UK) and Mast
discs (Mast group, UK). The inhibition zone diameter
was measured using caliper and recorded on excel sheet.
Data quality control
Standard operating procedures (SOPs) were strictly
followed while we did all bacteriological procedures
starting from sample collection, isolation, identification
and antibiotic susceptibility testing. Susceptible Ameri-
can Type Culture Collection (ATCC) 25,922 E. coli and
ATCC 25923 Staphylococcus aureus were used as con-
trol strains and the test results were only accepted when
the inhibition zone diameters of the above mentioned
control strains were within performance ranges as de-
scribed by CLSI [23]. ESBL positive ATCC 700603 Kleb-
siella pneumoniae and both ESBL and carbapenemase
negative E. coli ATCC 25922 control strains were used
in this study as positive and negative control respect-
ively. To standardize the inoculum density of bacterial
suspension for a susceptibility test, 0.5 McFarland stan-
dards, which is comparable with the approximate num-
ber of bacterial suspension (1.0 × 108 to 2.0x108bacteria/
mL), was used [23].
Data analysis and statistical tests
Data were double entered to Epi Data version 3.1 and
transferred to SPSS version 20 and Microsoft Excel soft-
ware for analysis and the results were presented as
tables, pie-charts and graphs. P-values < 0.05 were con-
sidered as statistically significant.
Ethical consideration
The study was approved by the Institutional Review
Board of Institute of Health, Jimma University. Informed
written consent was also obtained from participants
and/or guardians after explaining the objective of the
study. All the laboratory results were communicated as
early as possible with the treating physicians for better
management of the patients.
Result
Socio-demography and background information of the
participants
From 1015 patients who were enrolled in the study; only
197 admitted patients had developed sign of healthcare
associated infection with in the study time. Of these, 118
(59.9%) patients had culture confirmed healthcare asso-
ciated infections. Sociodemographic and clinical charac-
teristics of study participants have recently been
published. The incidence and overall prevalence of HAIs
at the hospital were 28.15 per 1000 patient days and
19.41% respectively [22].
Isolation rate
Totally 240 clinical samples were obtained from 192 pa-
tients who were clinically diagnosed with healthcare as-
sociated infection. The most common sources of
specimen were urine (55%) followed by wound swab/pus
(24.2%), blood (15%), and sputum (5.8%). A total of 126
bacterial pathogens were isolated from 118 patient sam-
ples. A single organism was isolated from 110 (93.2%)
patient samples, and two organisms were isolated from 8
(6.8%) patient samples who had been admitted to ICU.
The overall culture positivity rate of participants was
118/192(61.5%). Most commonly isolated bacteria were
E. coli 31(24.6%), Klebsiella species 30(23.8%) and S.
aureus 26 (20.6%) (Fig. 1).
Drug resistance patterns of isolates to different classes of
antibiotics
Antibiotic resistance patterns of the isolated patho-
gen of nosocomial origin are shown in Table 1. Half
of S. aureus isolates were resistant to gentamicin
50.0% (13/26); and 53.84% (14/26) and 57.7% (15/26)
of the isolates were resistant to methicillin /cefoxi-
tin/oxacillin and ceftriaxone/chloramphenicol in vitro
respectively; and all of S. aureus isolates were resist-
ant against penicillin (Table 1). From a total of 26 S.
aureus isolates, 3(11.5%), 10(38.5%) 10 (38.5%) and
3(11.6%) were MoDR, MDR, XDR and PDR respect-
ively (Table 2).
From Gram negative bacteria, E. coli and Klebsiella
species were the most frequent isolates. More than
90% of E. coli isolates were resistant against ampicil-
lin, tetracycline and trimethoprim-sulfamethoxazole
(Table 1). Conversely, only 16.1% of E.coli isolates
were resistant against meropenem. Likewise, the re-
sistance rate of Klebsiella species were 100% for
ampicillin, 90% for tetracycline, 80% for trimethoprim
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-sulfamethoxazole, 40% for ciprofloxacin and 30% for
meropenem (Table 1).
Classification of isolates based on their drug resistance
pattern
As shown in Table 2, among 126 bacterial isolates, 38
(30.2%), 52 (41.3%), and 24 (19%) were MDR, XDR, and
PDR respectively. Eight of the isolates were resistant to a
single antimicrobial class and only four Klebsiella isolates
were susceptible to all classes of the antimicrobials. The
predominant isolates (E. coli, Klebsiella species and S. aur-
eus) showed very high antimicrobial resistance patterns.
The overall MDR rate of the isolated bacteria was 30.16%.
All bacteria isolated from ICU and pediatrics wards, 87.5%
of bacteria isolated from Gynecology and obstetrics wards,
88% of bacteria isolated from Medical wards and 85.7% of
bacteria isolated from surgical wards were MDR. The
overall prevalence of PDR among all isolates was 19.0%.
Citrobacter species (45.4%) and Pseudomonas aeruginosa
(33.3%) have shown high pandrug resistance rate. On the
Fig. 1 Proportions of isolated bacterial pathogens
Table 1 Frequency of antimicrobial resistant bacterial isolates for selected antimicrobial classes
Antibiotic classes Antibiotics S. aureus
(n = 26)
E. coli
(n = 31)
Klebsiella
species
(n = 30)
Citrobacter
species
(n = 11)
P. aeruginosa
(n = 9)
Enterobacter
species
(n = 6)
Proteus
species
(n = 6)
Providencia
species
(n = 4)
A. buamannii
(n = 2)
Serratia
species
(n = 1)
Penecillins
3rd and 4th
generation
cephalosporins
Penicillin 26 – – – – – – – – –
Ampicillin – 29 30 11 9 6 5 4 2 1
Ceftriaxone 15 15 16 7 9 4 4 2 2 1
Ceftazidime – 16 17 8 8 5 4 2 2 1
Cefepime – 14 15 6 5 2 4 2 2 1
Anti-staphylococcal
β-lactams
Oxacillin 14 – – – – – – – – –
Cephamycins Cefoxitin 14 19 23 6 8 6 4 1 2 1
Aminoglycosides Gentamycin 13 22 21 7 8 3 3 1 2 1
Phenicols Chloramphenicol 15 19 20 8 9 1 3 3 2 1
Macrolides Erythromycin 19 – – – – – – – – –
Lincosamides Clindamycin 17 – – – – – – – – –
Tetracycline Tetracycline 17 29 27 7 9 4 6 4 2 1
Folate pathway
inhibitors
Trimethoprim-
sulfamethoxazole
19 28 24 9 4 2 6 3 2 1
Fluoroquinolones Ciprofloxacin 16 14 12 6 6 3 3 2 1 1
Carbapenems Meropenem – 5 9 2 4 1 0 1 2 1
Penecillins +
β-lactamase
inhibitors
Amoxicillin-
clavulanic acid
– 28 29 9 9 6 6 4 2 1
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other hand, Klebsiella species (6.6%) and S.aureus
(11.5%) have shown the least PDR rate. E.coli (22.6%)
and Enterobacter species (16.7%) have also shown a
moderate PDR rate.
Prevalence of ESBL, AmpC, and Carbapenemase
producing isolates
Of the 1 hundred isolated gram-negative rods, 36 and
7% were positive for extended spectrum beta-lactamase
(ESBL) and AmpC respectively. Eight percent of the
isolates were positive for both extended spectrum beta-
lactamase (ESBL) and AmpC. With regard to the pro-
portion of carbapenemase producing isolates, 25% of
gram negative isolates have shown carbapenem resist-
ance (Table 3). To be precise, 16.1% of E.coli and 30.0%
of Klebsiella species were carbapenem resistant isolates
(Table 3).
Antimicrobial resistance pattern and impact on clinical
outcome
Of 118 patients with culture confirmed healthcare asso-
ciated infection, 13 patients (11.02%) died and all of the
isolated microorganisms from these 13 patients were
multidrug resistant (MDR) as shown in Table 4. The
mean hospital stays of the patients infected with MDR
bacteria were 15.4 ± 9.6 days (range 3–49 days). There is
statistically significant association between mean dur-
ation of stay and infection with MDR bacteria (Table 4).
Discussion
The overall rate of MDR, XDR and PDR bacterial iso-
lates from JUMC were found to be 30.16, 41.27 and
19.0% respectively. Furthermore, the observed MDR rate
is significantly associated with prolonged hospital stay
and all patients, who died, were infected with MDR bac-
terial species (even if, it is not statistically significant).
On the other hand, the observed XDR and PDR rate at
the hospital indicates that the problem of AMR is in-
creasing at an alarming rate and pathogenic bacteria that
circulate in JUMC are becoming more resistant to all
available antibiotics. The occurrence of PDR pathogenic
bacteria would also have huge potential threat and impli-
cations for patient care in the hospital and the commu-
nity at large. As we are living in the era of very
connected world, it is highly likely for these PDR bac-
teria to be disseminated to other parts of Ethiopia and
other parts of the world as well.
To the best of our knowledge, there is no previous re-
port from Ethiopia on the rate of XDR and PDR patho-
genic bacteria to compare with this result. It is possible
to list some reasons which might have contributed for
this observed high XDR and PDR rate. The first reason
might be associated with lack of AMR surveillance and
stewardship program at JUMC and in Ethiopia in gen-
eral. There is enough evidence that indicates AMR sur-
veillance and stewardship program helps to understand
Table 2 Frequency distribution of MultiS, MoDR, MDR, XDR, and
PDR pattern of isolated bacteria
Isolated organisms Total MultiS MoDR MDR XDR PDR
S. aureus 26 0 3 10 10 3
E. coli 31 0 3 11 10 7
Klebsiella species 30 4 2 9 13 2
Citrobacter species 11 0 0 2 4 5
Enterobacter species 6 0 0 2 3 1
Proteus species 6 0 0 2 4 0
Providencia species 4 0 0 0 3 1
Pseudomonas aeruginosa 9 0 0 2 4 3
Acinetobacter baumannii 2 0 0 0 1 1
Serratia species 1 0 0 0 0 1
Total 126 4 8 38 52 24
MultiS, susceptible to all antibiotic classes; MoDR, resistant to single antibiotic
class; MDR, resistant to at least one agent in three or more antimicrobial
categories; XDR, resistant to at least one agent in all but two or fewer
antimicrobial categories (i.e. bacterial isolates remain susceptible to only one
or two categories); PDR, resistant to all antibiotic classes. Source: Based on
definitions by Magiorakos et al. [4]
Table 3 Prevalence of ESBL, AmpC, and Carbapenem resistant isolates of gram negative rods
Isolated organisms Total ESBL & AmpC producing isolates Carbapenemase resistance
Not ESBL & AmpC, N (%) ESBL, N (%) AmpC, N (%) ESBL & AmpC, N (%) Yes, N (%) No, N (%)
E. coli 31 12(38.7) 14(45.2) 3 (9.7) 2 (6.5) 5 (16.1) 26 (83.9)
Klebsiella species 30 14 (46.7) 13 (43.3) 2 (6.7) 1 (3.3) 9 (30.0) 21 (70.0)
Citrobacter species 11 5 4 0 2 2 9
Enterobacter species 6 2 3 0 1 1 5
Proteus species 6 5 1 0 0 0 6
Providencia species 4 1 2 1 0 1 3
Pseudomonas aeruginosa 9 5 1 1 2 4 5
Acinetobacter baumannii 2 2 0 0 0 2 0
Serratia species 1 1 0 0 0 1 0
Total 100 49 36 7 8 25 75
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the pattern of resistance and improve the utilization of
antibiotics to prevent occurrence of antibiotic resistance.
The second reason might be associated with lack
of comprehensive national antibiotic policies and
problems in implementations of policies. In Ethiopia,
there is no clear antibiotic policy and controlling
mechanism about antibiotic usage. It is a common
practice in Ethiopia to buy any antibiotic from pri-
vate drug vendors and pharmacies without any
prescription. This might have contributed for emer-
gence and dissemination of antibiotic resistant bac-
teria at different settings. The third reason might be
associated with lack of system to assess the quality
and reliability of imported antibiotics in Ethiopia.
For instance, one previous study which assessed the
quality of anti-tuberculosis drugs in Ethiopia in 2013
has indicated that around 17% of anti TB drugs were
fake drugs [24]. It is easy to imagine the role of
these fake drugs on anti TB drug resistance. Like-
wise, though there is no previous research done in
Ethiopia to assess the quality of antibiotics dispensed
in private and government pharmacies, it is highly
likely that some of them might be sub-standard,
given that substantial proportion of the antibiotics in
private pharmacies are supplied through unknown
routes [25, 26].
The emergence of ESBL producing gram negative
rods have become a rising concern in the developing
world [27]. In this study, phenotypically, the most
common ESBL producing microorganisms were E.
coli and Klebsiella species which are 51.6% (16/31)
and 46.7% (14/30) respectively; which is comparable
with the studies done in Nigeria, Nepal and Burma
in which ESBL producing Enterobacteriaceae were
44.3, 43.7 and 38.0% respectively [14, 28, 29]. How-
ever, the other studies done in India and Nepal
showed that 30.18 and 18.4% of Klebsiella pneumo-
niae produce ESBL respectively which is lower than
our report [30, 31]. Even though the prevalence of
ESBLs is not well documented, in many parts of the
world 10–40% of strains of Escherichia coli and
Klebsiella pneumoniae are estimated to produce
ESBLs [27]. High proportion of ESBL producing iso-
lates was documented in the current study which
might be due to the fact that our study participants
were all hospitalized; since hospitalization was iden-
tified as the strongest independent risk factor to ex-
press ESBL [32].
Regarding to carbapenem resistance, 19 (21.4%), 4
(44.4%) and 2 (100%) of the Enterobacteriaceae, P. aerugi-
nosa and A. buamannii were carbapenem resistant re-
spectively which are found in the priority one list
according to WHO classification [33]. In addition to that,
53.8% of the other commonly isolated S. aureus were
methicillin resistant which also needs high attention.
Therefore, high attention should be given to these patho-
gens which are considered as priority one and two accord-
ing to WHO [33]. To compare with other similar studies,
the rate of carbapenem resistance among E.coli (16.1%)
and Klebsiella species (30%) is consistent with multi-
national study done in Europe [34]. In contrary, 25% car-
bapenem resistance rate observed in this study is lower
than a report from Brazil which was 100% [35]. This could
be explained by the difference in utilization of carbapenem
antibiotics to treat different infections in the respective
setups [36, 37]. The observed high carbapenem resistance
rate can also be due to prescription of antibiotics without
the knowledge of their susceptibility pattern, or introduc-
tion and dissemination of carbapenem resistant bacteria
strains from other areas with high resistance rate might
also be possible as JUMC is frequently visited by different
European, Chinese and Korean nationalities due to differ-
ent collaborative researches, training and service activities.
As reported by other studies, meropenem was the most
effective antibiotic against most gram-negative rods [38].
To control high rate of antibiotic resistant isolates coordi-
nated and urgent action is needed to prevent the develop-
ment of drug resistance in the setting. Surveillance on
antibiotic resistance will also be most useful to decide the
correct empirical treatment and will help to control and
prevent infections caused by resistant pathogens. Further-
more, our data suggest that the most effective antibiotics
for gram-negative bacilli in vitro are meropenem followed
by cefepime and for gram-positive organisms less resist-
ance was observed against gentamycin.
Conclusion
In this study, high antimicrobial resistance rate was
demonstrated. The observed high PDR, ESBL and carba-
penem resistance rate is worrisome. Coordinated effort
Table 4 Antimicrobial resistance and associated factors
Variable Non MDR (N = 12) (%) MDR (N = 106) (%) P
History of treatmenta
No 9 (75.0) 85 (80.19)
Yes 3 (25.0) 21 (19.81) 0.672
Patient outcome
Progress 12 (100) 93 (87.74)
Died 0 13 (12.26) 0.198
Duration of stay in Hospital
<=15 days 8 (66.6) 25 (23.58)
> 15 days 4 (33.4) 81 (76.42) 0.002
Non-MDR: susceptible to all antibiotic classes/resistant to one/two antibiotic
classes; MDR: resistant to at least one agent in three or more antimicrobial
categories Magiorakos et al. [4]
a taking antibiotics in the last 3 months of the study period
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is needed from all stakeholders working in health sys-
tem in Ethiopia to tackle this important public health
problem. An immediate action should be taken at the
hospital to start antibiotic stewardship program to re-
duce the observed antibiotic resistance and prevent
further complications.
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